Serial InBody assessments reveal adaptation through: Falling BMR despite maintained or reduced weight Muscle loss with simultaneous fat regain after stopping therapy Slower weight loss plateau despite continued medication Declining phase angle indicates cellular health deterioration Tracking these trends is essential for understanding why weight regain is common after stopping GLP-1 therapy and why concurrent muscle preservation strategies are non-negotiable in any complete semaglutide management programme
Long-term success will depend on clinical differentiation, real-world evidence, payer value, patient support programs, adherence tools, physician education, and clear positioning across obesity, type 2 diabetes, cardiovascular risk and metabolic syndrome
Many insurance plans in California , including those covering patients in Los Angeles , West Hollywood , and Beverly Hills , may cover GLP-1 weight loss medications but approval often depends on strict medical criteria
It is also involved in improving recovery after injuries
With waitlists growing and prices soaring, many are searching for alternatives
Both can work exceptionally well when paired with consistency and movement